Geron shares slide on disappointing trial results

Shares of Geron slid more than 10 percent this morning after the company reported that its cancer therapy appeared to have no significant affect on leukemia cells in a Phase I/II trial. Researchers highlighted data demonstrating that the therapy was well tolerated by patients.

"Up to the current dose levels, no significant changes in telomerase activity or telomere length in the bulk circulating CLL cells of treated patients have been observed," reported the company. "These pharmacodynamic results are consistent with expectations because of the relatively short exposure of CLL cells in patients' blood to concentrations of drug capable of inhibiting telomerase."

- see this press release

Suggested Articles

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.